LAMB2 and neoplasm: Bortezomib was observed to be more potent against GBM6 GSCs (GBM6 spheroids or in laminin) than against the differentiated GBM6 (bulk tumour) or the U87 cell line, suggesting Bortezomib may specifically affect the master regulators of the GSCs.